Stockreport

AnaptysBio: Trial of Jemperli Drug Meets Primary Endpoint [MarketWatch]

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF Jemperli, met its primary endpoint of investigator-assessed progression-free survival. The San Diego, Calif., clinical-stage biotechnology company reported that GSK PL [Read more]